These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34099670)

  • 41. The molecular pathogenesis of Barrett's esophagus: common signaling pathways in embryogenesis metaplasia and neoplasia.
    Peters JH; Avisar N
    J Gastrointest Surg; 2010 Feb; 14 Suppl 1():S81-7. PubMed ID: 19760304
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Changes in mitochondrial stability during the progression of the Barrett's esophagus disease sequence.
    O'Farrell NJ; Feighery R; Picardo SL; Lynam-Lennon N; Biniecka M; McGarrigle SA; Phelan JJ; MacCarthy F; O'Toole D; Fox EJ; Ravi N; Reynolds JV; O'Sullivan J
    BMC Cancer; 2016 Jul; 16():497. PubMed ID: 27431913
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Toll-like Receptor 2 Signalling and the Lysosomal Machinery in Barrett's Esophagus.
    Verbeek RE; Siersema PD; Vleggaar FP; Ten Kate FJ; Posthuma G; Souza RF; de Haan J; van Baal JW
    J Gastrointestin Liver Dis; 2016 Sep; 25(3):273-82. PubMed ID: 27689189
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma.
    Yang H; Gu J; Wang KK; Zhang W; Xing J; Chen Z; Ajani JA; Wu X
    Clin Cancer Res; 2009 Sep; 15(18):5744-52. PubMed ID: 19737949
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glutathione S-transferase-pi expression is downregulated in patients with Barrett's esophagus and esophageal adenocarcinoma.
    Brabender J; Lord RV; Wickramasinghe K; Metzger R; Schneider PM; Park JM; Hölscher AH; DeMeester TR; Danenberg KD; Danenberg PV
    J Gastrointest Surg; 2002; 6(3):359-67. PubMed ID: 12022988
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids.
    Peng S; Huo X; Rezaei D; Zhang Q; Zhang X; Yu C; Asanuma K; Cheng E; Pham TH; Wang DH; Chen M; Souza RF; Spechler SJ
    Am J Physiol Gastrointest Liver Physiol; 2014 Jul; 307(2):G129-39. PubMed ID: 24852569
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
    Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus.
    Guillem P; Billeret V; Buisine MP; Flejou JF; Lecomte-Houcke M; Degand P; Aubert JP; Triboulet JP; Porchet N
    Int J Cancer; 2000 Dec; 88(6):856-61. PubMed ID: 11093805
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Origin of adenocarcinoma in Barrett's esophagus: p53 and Ki67 expression and histopathologic background.
    Szachnowicz S; Cecconello I; Iriya K; Marson AG; Takeda FR; Gama-Rodrigues JJ
    Clinics (Sao Paulo); 2005 Apr; 60(2):103-12. PubMed ID: 15880245
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Downregulation of TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L in Barrett's esophagus with dysplasia and adenocarcinoma.
    Popnikolov NK; Gatalica Z; Adegboyega PA; Norris BA; Pasricha PJ
    Appl Immunohistochem Mol Morphol; 2006 Jun; 14(2):161-5. PubMed ID: 16785783
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trefoil factor 1 inhibits the development of esophageal adenocarcinoma from Barrett's epithelium.
    Hasebe K; Yamazaki K; Yamaguchi J; Kokuryo T; Yokoyama Y; Miyata K; Fukaya M; Nagino M; Ebata T
    Lab Invest; 2022 Aug; 102(8):885-895. PubMed ID: 35279702
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression of CDX2 and MUC2 in Barrett's mucosa.
    Steininger H; Pfofe DA; Müller H; Haag-Sunjic G; Fratianu V
    Pathol Res Pract; 2005; 201(8-9):573-7. PubMed ID: 16259110
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Notch Signaling Mediates Differentiation in Barrett's Esophagus and Promotes Progression to Adenocarcinoma.
    Kunze B; Wein F; Fang HY; Anand A; Baumeister T; Strangmann J; Gerland S; Ingermann J; Münch NS; Wiethaler M; Sahm V; Hidalgo-Sastre A; Lange S; Lightdale CJ; Bokhari A; Falk GW; Friedman RA; Ginsberg GG; Iyer PG; Jin Z; Nakagawa H; Shawber CJ; Nguyen T; Raab WJ; Dalerba P; Rustgi AK; Sepulveda AR; Wang KK; Schmid RM; Wang TC; Abrams JA; Quante M
    Gastroenterology; 2020 Aug; 159(2):575-590. PubMed ID: 32325086
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased expression of epidermal growth factor receptors in Barrett's esophagus associated with alkaline reflux: a putative model for carcinogenesis.
    Jankowski J; Hopwood D; Pringle R; Wormsley KG
    Am J Gastroenterol; 1993 Mar; 88(3):402-8. PubMed ID: 8438848
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Large intra- and inter-individual variability of genes expression levels limits potential predictive value of molecular diagnosis of dysplasia in Barrett's esophagus.
    Hennig EE; Mikula M; Orlowska J; Jarosz D; Bielasik A; Regula J; Ostrowski J
    J Mol Med (Berl); 2008 Feb; 86(2):233-42. PubMed ID: 17952395
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Forced expression of HOXA13 confers oncogenic hallmarks to esophageal keratinocytes.
    Nesteruk K; Janmaat VT; Liu H; Ten Hagen TLM; Peppelenbosch MP; Fuhler GM
    Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165776. PubMed ID: 32222541
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High risk of malignancy in familial Barrett's esophagus: presentation of one family.
    Munitiz V; Parrilla P; Ortiz A; Martinez-de-Haro LF; Yelamos J; Molina J
    J Clin Gastroenterol; 2008 Aug; 42(7):806-9. PubMed ID: 18385604
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
    Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):727-31. PubMed ID: 18349295
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The pathogenesis of Barrett's esophagus: secondary bile acids upregulate intestinal differentiation factor CDX2 expression in esophageal cells.
    Hu Y; Williams VA; Gellersen O; Jones C; Watson TJ; Peters JH
    J Gastrointest Surg; 2007 Jul; 11(7):827-34. PubMed ID: 17458588
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A newly identified susceptibility locus near FOXP1 modifies the association of gastroesophageal reflux with Barrett's esophagus.
    Dai JY; de Dieu Tapsoba J; Buas MF; Onstad LE; Levine DM; Risch HA; Chow WH; Bernstein L; Ye W; Lagergren J; Bird NC; Corley DA; Shaheen NJ; Wu AH; Reid BJ; Hardie LJ; Whiteman DC; Vaughan TL
    Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1739-47. PubMed ID: 26377193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.